QLS‑111 is a novel topical formulation using Qlaris Bio’s ATP-sensitive potassium channel modulator platform. QLS-111 lowers ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

Qlaris Bio is seeing double when it comes to phase 2 wins for its eye drug, hitting the primary endpoints in trials that both spanned primary open angle glaucoma (POAG) and ocular hypertension (OHT).

A cervical cancer drug may elevate the risk of developing ocular surface disease, such as conjunctival scarring and infectious keratitis.

Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced positive topline results from two U.S. Phase II clinical trials ...

No serious adverse events were reported, nor did investigators observe any clinically meaningful hyperemia or other ocular or systemic adverse events. In addition, no incremental hyperemia was ...

If you ever notice pesky dark strands that may resemble anything from a simple speck to a cobweb drifting across your vision, what you're probably seeing is what's known as an eye floater. Floaters ...

No serious adverse events were reported, nor did investigators observe any clinically meaningful hyperemia or other ocular or systemic adverse events. In addition, no incremental hyperemia was ...

Yellow or green discharge (pus) in the eye The eyelids are stuck (matted) together with pus after sleep After being wiped away, the pus comes back during the day Often caused by a bacterial eye ...